Naturally Splendid Enterprises greenlit to begin Phase 2 study for its potential COVID-19 treatment

Biologic Pharmamedical CEO Franco Cavaleri tells Proactive the group, together with Naturally Splendid Enterprises Ltd (CVE:NSP) (OTCQB:NSPDF) has received a Notice of Authorization from Health Canada to proceed with a Phase 2 clinical trial for a potential COVID-19 treatment utilizing the target drug Cavaltinib. Cavaleri says within 60-90 days the company should be able to begin the trial. Cavaleri says he hopes Cavaltinib will show positive results in mitigating the 'cytokine storm' with COVID-19 patients